# Harvoni

NDC: 61958-1804
Generic name: ledipasvir and sofosbuvir
Labeler / Manufacturer: Gilead Sciences, Inc
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: PELLET
Routes: ORAL
Marketing started: 20190828

FDA application: NDA212477

## Active ingredients

- LEDIPASVIR: 45 mg/1
- SOFOSBUVIR: 200 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"61958-1804"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=61958-1804
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075